GNRH1 and pachyonychia congenita: Using daily doses of LHRH agonists to treat advanced PC patients demonstrated a 75% decrease in serum testosterone levels, a decrease or normalization of plasma acid phosphatase levels, and, most importantly, a significant decrease in cancer-associated bone pain [36].